Industry News

• Teva announces update on Fremanezumab clinical development for episodic cluster headache  Teva announces it is discontinuing clinical development program for use of fremanezumab in cluster headaches. A pre-specified futility analysis of a Phase III study in episodic cluster headache revealed that the study’s primary endpoint is unlikely to be met.
  April 23, 2019  
• ChemioCare announces initiation of PETT based lenalidomide program  ChemioCare USA announced it is initiating development of a transdermal formulation of lenalidomide, which is currently marketed in an oral form. The benefits of transdermal delivery may transform lenalidomide PETT into a new superior drug profile.
  April 23, 2019  
• Surmodics Sublime™ guide sheath receives FDA 510(k) approval  Surmodics announced it has received FDA 510(k) clearance for its Sublime™ guide sheath. The sheath will be available in 5Fr and 6Fr diameters, and 120cm and 150cm lengths. The entire working length of the guide sheath is Serene® hydrophilic coated to provide a lubricious surface.
  April 23, 2019  
• Clinical data highlights advantages of protected PCI to enable complete revascularization   New research adds to 12 years of real-world data and FDA studies demonstrating the use of Abiomed's Impella heart pumps during high-risk PCI enables skilled interventional cardiologists to achieve more complete revascularization, improved ejection fraction and quality of life.
  April 23, 2019  
• Cambrex completes new quality control laboratory for generic API development in Milan  Cambrex announced it had opened a new 120m2 quality control laboratory at its site in Paullo, Milan, Italy. The laboratory expands on the current QC facilities that analyze and test its generic API portfolio of products during development and manufacturing.
  April 23, 2019  
• Japan cell therapy transaction yields $3MM  Cytori Therapeutics announced a transaction to divest certain cell therapy assets to Seijirō Shirahama of Tokyo, Japan yielding $3MM in non-dilutive funding to the Company, before related transaction expenses.
  April 23, 2019  
• Trovagene announces data demonstrating significant synergy of Onvansertib  Trovagene announced preclinical data that evaluated the effect of combining onvansertib with venetoclax in an AML cell model known to be resistant to venetoclax (Venclexta® - AbbVie). This combination demonstrated synergy with a significant decrease in tumor cell viability.
  April 23, 2019  
• OncoSec announces triple combination immunotherapy clinical trial  OncoSec Medical announced a triple combination clinical trial of OncoSec's TAVO(TM), epacadostat, and KEYTRUDA(R) in patients with squamous cell carcinoma head and neck cancer. This study, the "TRIFECTA" study, will be conducted by the UCSF Helen Diller Family Comprehensive Cancer Center.
  April 23, 2019  
• Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast cancer  Roche announced the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for detection of the HER2 biomarker in breast and gastric cancer. HER2 is an important biomarker found in breast and gastric cancers.
  April 23, 2019  
• Teva announces launch of generic VESIcare® (solifenacin succinate) tabletsin the U.S.  Teva announced the launch of a generic version of VESIcare® (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S. Solifenacin Succinate Tablets are a muscarinic antagonist indicated for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
  April 22, 2019  

   (next 10 articles)